Searched for
CANCER DRUG PRICE CUTS
Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% r...
Dr Reddy's bets on generic semaglutide, biosimilarsDr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of gene...
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trialJohnson & Johnson reported results from an early-stage trial of their prostate cancer drug JNJ-6143. The trial involved patients with advan...
DRL says cap on trade margins a positive, posts 36% dip in Q2 PATIn the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trad...
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug developmentPathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence too...
GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan saysThe China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan esti...
Hospitals overcharge patients upto 700% on medicines while India makes some of the world’s lowest priced drugs: Centre admits to SCGovt has told Supreme Court that hospitals overcharging patients for medicines and medical consumables is a malpractice. Its affidavit cite...
Sanofi healthcare receives CDSCO approval for Qftilia therapy for haemophilia patients in IndiaSanofi Healthcare has obtained authorisation from the Central Drugs Standard Control Organisation for Qfitlia. This therapy is designed to ...
Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancerDr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new...
NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov 9India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. ...
The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reachFor millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...
Protect patients and patents smartlyThe Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...
Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possibleAn expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...
SC asks govt to broaden inflated pricing review beyond oncologyThe Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...
Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicinesThe Supreme Court expressed its worry over the government's restriction of price control measures to only anti-cancer drugs, questioning wh...
Cancer drugs may get up to 70% cheaper as govt fixes trade margins on non-scheduled medicines at 30%The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...
Govt set to cap trade margins on more cancer drugs before SC hearingThe Indian government plans to announce a new list of cancer drugs for trade margin rationalisation today. Union Health Minister JP Nadda w...